Amryt Pharma

Industry · 9 registered clinical trials — 6 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy Generalized Lipodystrophy	Phase 3	2025-05-23
Recruiting	A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional	—	2024-12-18
Recruiting	Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Familial Partial Lipodystrophy	Phase 3	2024-10-14
Recruiting	Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Partial Lipodystrophy	Phase 4	2024-02-08
Active Not Recruiting	Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL Partial Lipodystrophy	Phase 3	2021-12-17
Completed	Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) Homozygous Familial Hypercholesterolaemia (HoFH)	Phase 3	2020-12-14
Recruiting	MEASuRE: Metreleptin Effectiveness And Safety Registry Generalised Lipodystrophy, Partial Lipodystrophy	—	2016-10-11
Terminated	Global Lomitapide Pregnancy Exposure Registry Pregnancy	—	2014-10-01
Recruiting	LOWER: Lomitapide Observational Worldwide Evaluation Registry Homozygous Familial Hypercholesterolemia	—	2014-03-18